ArticleMovement disorders clinical practice2015
Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease.
Article in Movement disorders clinical practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Health-related quality of life in Parkinson's disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Depression and Mood Changes in People with Parkinson's Disease over Time: A 5-Year Follow-Up Study.Journal of personalized medicine · 2026Article
- Optimizing Identification and Management of Depression in Neurological Diseases: A Narrative Review and Expert Perspective.Neuropsychiatric disease and treatment · 2026Article
- Efficacy and safety of adjunctive acupuncture for depression and motor symptoms in Parkinson's disease: study protocol for a randomized controlled trial.Frontiers in psychiatry · 2026Article
- A transdiagnostic, multi-modal approach to understanding apathy: Methodological and analytical framework.Neuroimage. Reports · 2025Article
- Non-Motor Symptoms as Markers of Disease Severity in Parkinson's Disease: Associations Between Constipation, Depression, REM Sleep Behavior Disorder, and Motor Impairment.Biomedicines · 2025Article
- When Sex Overcomes Motor Phenotype: New Evidence on Cognitive and Neurobehavioral Symptoms in Parkinson's Disease.Brain and behavior · 2025Article
- Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease.NPJ Parkinson's disease · 2025Article
- Neuropsychiatric disorders in Parkinson's disease.Therapeutic advances in neurological disorders · 2025Review
- Neuroanatomical and prognostic associations of depression in Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis.The Lancet regional health. Europe · 2024Article
- The pathobiological basis of depression in Parkinson disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.Drugs & aging · 2022Review
- The natural history of depressive symptoms in patients with incident Parkinson's disease: a prospective cohort study.Journal of neurology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 12 institutions in 1 country.
Funding
Abstract
backgroundDepression is one of the most common nonmotor symptoms associated with Parkinson's disease (PD), yet the impact of depression on progression of disease is unclear.
objectiveThe aim of this study was to prospectively characterize the relationship between depressive symptoms and measures of disease progression in a large sample of patients with early, medically treated PD.
methodsBaseline and longitudinal Beck Depression Inventory (BDI) scores from participants in the NINDS Exploratory Trials in PD Long Term Study 1 were correlated with changes in multiple measures of disease severity over 5 years. Multivariate analysis of predictors of change in BDI was performed.
resultsOf 1,741 participants, 746 completed 5-year assessments and were included. Mean age was 62.00 years (standard deviation [SD]: 9.22) and mean disease duration was 1.69 years (SD, 1.16). Mean BDI score was 6.24 (SD, 5.02) at baseline and 8.57 (SD, 6.60) at 5 years. Baseline BDI score was strongly associated with rate of change in all examined measures of disease severity. In multivariate analysis, BDI 5-year change was associated with change in UPDRS Part I (excluding depression item;
conclusionsWorse baseline BDI scores are associated with a decline in multiple measures of disease severity in PD. Worsening of BDI at 5 years was associated with worsening in UPDRS Part I and quality-of-life measures, but not with motor or cognitive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.